Openly prescribed placebos to reduce symptoms of allergic rhinitis

Providing open-label placebos remotely – a randomized controlled trial in allergic rhinitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11274834

Enrollment

Registered

2021-05-04

Start date

2020-04-20

Completion date

Unknown

Last updated

2022-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis Respiratory

Interventions

Participants received either open-label placebo plus treatment as usual (TAU) or TAU alone for their allergic rhinitis over the course of two weeks TAU+OLP If particip

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed allergic rhinitis 2. At least 18 years old 3. Sufficient German language skills

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Diabetes 3. Any mental or neurological illness 4. Lactose intolerance

Design outcomes

Primary

Measure	Time frame
Allergic symptoms measured using the combined symptom medication score (CSMS) at baseline and two weeks	—

Secondary

Measure	Time frame
Impairment caused by allergic symptoms measured using the adapted version of the Pain Disability Index (PDI) at baseline and two weeks	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026